QoL (WHOQOL-BREF), perception of disease (B-IPQ), symptoms of the disease (QLQ-PR25) and perception of cohesion within the patient-partner relationship (dyadic adjustment, . The results are presented as mean AE standard deviation. The final analysis included 492 patients (74.2 years AE 8.1), including 470 with a partner evaluation (70.5 AE 9.0 years).
INTRODUCTION AND OBJECTIVES:
Although men with newly-diagnosed oligometastatic prostate cancer have historically been treated with androgen deprivation therapy (ADT), emerging evidence suggests local treatment of the primary tumor may improve survival. Recent randomized trials have also demonstrated benefit from combination docetaxel with ADT for men with naive metastatic cancer. The use neoadjuvant chemo-hormonal therapy in conjunction with local consolidative treatment in this setting, however, has not previously been described. We present the initial surgical outcomes of a novel protocol.
METHODS: A phase II study conducted at our institution began accruing patients in 2016. Men with newly diagnosed oligometastatic prostate cancer (T1-4, N0-1, M1a-b) consisting of 5 metastatic lesions were treated with the following: (1st) systemic therapy with up to 6 months of neoadjuvant ADT and 6 cycles of docetaxelþADT, (2nd) consolidation with radical prostatectomy (RP) AE adjuvant radiation therapy (XRT), and (3rd) AE stereotactic radiation (SBRT) to oligometastatic lesions.
RESULTS: To date, 18 patients have enrolled in the study: 17 have undergone RP and 1 is currently receiving neoadjuvant systemic therapy. For men undergoing surgery, median age was 58.0 years (IQR 55.0-64.0) with median follow-up of 10.1 months (IQR 4.1-13.2). Patients had a median 2 sites of metastases (IQR 1.0-3.0) and PSA 15.9 (IQR 7.2-66; range, 3.6-953) at diagnosis. Patients received a median of 12 months of ADT and 4 cycles of Docetaxel; median PSA after systemic therapy was 0.6 (IQR 0.2-1.6). Median operative time, blood loss, and length of hospitalization were 177.5 min ), 200 ml (IQR 137.5-450.0), and 1 day (IQR 1.0-1.3), respectively. Six patients underwent open and 11 underwent robotassisted RP with a 23.6% perioperative transfusion rate overall -2 patients in the open group and 2 in the robot group. One patient (5.9%) experienced a Clavien grade II complication (hematuria with UTI); the other three experienced Clavien grade III complications (hematuria in 1 patient, bladder neck contractures requiring dilation in 2 patients). The majority (13 patients, 76.5%) had !ypT3a disease and 5 (47.1%) had positive surgical margins. Lymph node dissection yielded a median 13.5 nodes (IQR 9.8-22.3), and 7 (41.1%) men had lymph node metastases. Seven patients (41.1%) have undergone adjuvant XRT and 9 (52.9%) have completed SBRT, to date. All 17 patients thus far have obtained post-RP PSA levels, all of which are undetectable.
CONCLUSIONS: The combination of neoadjuvant chemohormonal therapy with definitive local therapy and SBRT for patients with oligometastatic prostate cancer appears feasible based on initial surgical outcomes. This management paradigm presents a possible future option for the treatment of men with oligometastatic prostate cancer. Longer-term safety, survival, and functional outcomes from this study are forthcoming.
Source of Funding: None
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INTRODUCTION AND OBJECTIVES: Androgen deprivation therapy (ADT) for the treatment of prostate cancer has been shown, albeit not consistently, to be related to specific consequences such as incident depression. The presence of depressive symptoms in patients with advanced disease eligible for ADT is less well understood. The current study was undertaken to estimate the prevalence and predictors of depression in a contemporary sample of patients beginning ADT.
METHODS: Data from the current study were drawn from the RADICAL PC study, a parent prospective cohort study conducted across 13 sites in Canada. Men with prostate cancer initiating ADT for the first time were recruited. Depressive symptoms were evaluated using the 9 item version of the Patient Health Questionnaire (PHQ-9). A score of 8 or higher on this scale represents clinically relevant depressive symptoms. To evaluate predictors of depressive symptoms, a logistic regression model was constructed including biological, psychological, and social predictor variables. RESULTS: Data from 407 patients were available at the time of this analysis. Of these, 43 (10.6%) endorsed clinically significant burden of depressive symptoms. Two variables were identified as independent predictors of depression -poor functional status (OR[5.18, p<0 .001) increased depression risk, whereas being retired was found to be protective (OR[0.37, p[0.03) . Indicators of advanced disease (e.g. presence of metastatic disease) were not associated with depression in either univariate or multivariate models.
CONCLUSIONS: Our multi-centre study of depressive symptoms among prostate cancer patients starting ADT shows that these symptoms are already present in a sizeable sample of men. These do not seem to be affected by disease-related indicators, but rather are better predicted by psychosocial variables. Clinicians should be suspicious of poor psychological functioning especially among those prostate cancer patients with poorer functional status. Moving forward, it will be important to document the incidence and change in depressive symptoms as these patients begin ADT and are followed prospectively.
